HBOT for Chronic Conditions: What the Evidence Shows by Condition

Hyperbaric oxygen therapy (HBOT) has strong, FDA-cleared evidence for a few chronic conditions driven by poor tissue oxygenation, including diabetic foot ulcers, chronic radiation injury, and refractory osteomyelitis. For most other chronic conditions the evidence is moderate, emerging, or absent. In the best-studied off-label use, fibromyalgia, a 2023 meta-analysis of 9 studies (288 patients) found significant pain reduction, though the only double-blind trial found no benefit over pressurized air. This guide grades each condition honestly.

Chronic conditions are the most complex territory in HBOT research because they involve systemic pathology across multiple organ systems. This page covers metabolic disease, autoimmune conditions, post-infectious syndromes, and pain conditions, and is transparent throughout about where the evidence is strong, where it is preliminary, and where HBOT remains speculative.

Does HBOT Work for Chronic Conditions?

For a small group of chronic conditions, yes, with FDA-cleared support. For most, HBOT is off-label with evidence ranging from moderate to none. The unifying rationale is tissue hypoxia: conditions where impaired oxygen delivery is central to the pathology respond better than conditions where oxygen is peripheral to the disease.

Many chronic diseases share tissue-level hypoxia, whether from impaired microvascular circulation in diabetes, vascular damage after radiation, or autonomic dysregulation after infection. HBOT saturates plasma with dissolved oxygen and reaches areas of compromised perfusion that normal circulation cannot supply. Stephen Thom’s 2011 review in Plastic and Reconstructive Surgery describes the downstream biology: reactive oxygen and nitrogen species act as signaling molecules that drive angiogenesis, mobilize bone-marrow stem cells, and modulate inflammation. Hadanny and Efrati (2020) framed the newer idea of the hyperoxic-hypoxic paradox, in which intermittent high oxygen followed by a return to normal triggers the same regenerative genes that hypoxia does.

The important caveat is that a plausible mechanism is not proof of benefit. A 2026 systematic review by Leys and colleagues of 11 RCTs (480 chronic-pain patients) found consistent within-group improvements in pain and function, but noted that most trials lacked adequate blinding, which limits how much weight the results carry. For the mechanistic background, see our HBOT research hub, and for safety before any treatment, our guide to hyperbaric chamber side effects.

Which Chronic Conditions Have the Strongest Evidence?

The strongest evidence is for conditions with a clear vascular or hypoxic mechanism: diabetic foot ulcers, chronic radiation tissue injury, and refractory osteomyelitis are all FDA-cleared. Fibromyalgia has the best off-label evidence base but mixed blinded results. Long COVID and IBD are emerging. The table below grades each condition with its key study and sample size.

The FDA-cleared chronic indications share a common thread: they are conditions of failed vascularity that HBOT’s angiogenic mechanism directly targets. Diabetic foot ulcers threatening amputation are covered by Medicare when properly documented; the diabetic foot ulcer data page has the clinical numbers, and our overview of HBOT for diabetes covers both established and emerging uses. Radiation cystitis, proctitis, and osteoradionecrosis respond to the same mechanism, covered in our articles on radiation cystitis and radiation damage. Chronic osteomyelitis, where poorly perfused bone resists antibiotics, is an approved adjunct discussed alongside HBOT for infections and bone repair. Exceptional blood-loss anemia, where HBOT sustains oxygen delivery in plasma when red cells are scarce, is covered in HBOT for anemia.

What Does the Evidence Show for Fibromyalgia?

Fibromyalgia has the most developed HBOT evidence among chronic pain conditions, but the picture is mixed. Multiple unblinded trials and meta-analyses show meaningful pain and quality-of-life improvement, while the single properly double-blinded trial found no benefit over pressurized air. The honest reading is moderate evidence with a real risk of placebo and pressure effects.

The landmark study is Efrati and colleagues’ 2015 crossover RCT of 60 women, in which 40 HBOT sessions produced significant improvement across fibromyalgia symptoms and quality of life, with SPECT brain imaging showing changes in activity patterns tied to central sensitization. Three meta-analyses followed. Chen and colleagues (2023) pooled 9 studies of 288 patients and found significant reductions in pain on the visual analogue scale and widespread pain index, plus better fatigue, function, and sleep. Cao and colleagues (2023) analyzed 4 RCTs of 163 patients and reported a large effect on the Fibromyalgia Impact Questionnaire (standardized mean difference -1.57). Kulshreshtha and colleagues (2024) reached similar conclusions on pain and tender-point count. More recent RCTs by Boussi-Gross (2024) and Ablin (2023) tested HBOT in fibromyalgia tied to childhood trauma and to traumatic brain injury, again reporting benefit.

The counterweight matters. The only truly double-blinded fibromyalgia study, Raffeiner and colleagues (2020), compared HBOT against hyperbaric air and found no significant difference between groups, with both improving. Every positive fibromyalgia trial either lacked blinding or used a waiting-list control, so the chamber experience itself may drive part of the effect.

“An 8-week course of hyperbaric oxygen did not substantially improve fibromyalgia symptoms compared with placebo hyperbaric air, and beliefs and expectations about the treatment should be considered.”
Raffeiner et al., 2020, EULAR congress abstract

Our full article on HBOT for fibromyalgia covers the complete evidence landscape, including protocol details.

Can HBOT Help Long COVID?

Long COVID is one of the most actively studied HBOT applications, and the trials genuinely conflict. Two sham-controlled RCTs from one Israeli group found significant cognitive, cardiac, and symptom improvements, while an independent Swedish trial found no benefit over placebo. This is emerging evidence with a real replication question, not settled science.

On the positive side, Zilberman-Itskovich and colleagues (2022) randomized 73 post-COVID patients to 40 HBOT sessions or sham and found significant improvement in global cognitive function, attention, and executive function, with a large effect on psychological symptoms. Leitman and colleagues (2023) showed improved global longitudinal strain on echocardiography in a 60-patient sham-controlled trial, and Catalogna and colleagues (2024) reported that the cognitive gains persisted at long-term follow-up. A 2025 prospective registry in Scientific Reports found similar symptom improvements at scale.

On the negative side, the HOT-LoCO trial (2025) randomized 80 patients to 10 HBOT sessions or medical-air placebo and found no significant difference in physical function or role limitation at 13 weeks, with both groups improving. The two Israeli trials used 40 sessions while HOT-LoCO used 10, so dose may explain part of the gap, but the null result from an independent group is a caution. Our articles on HBOT for long COVID symptoms and the detailed long COVID clinical data cover the full trial-by-trial evidence.

What About IBD, MS, Autoimmune, and Other Conditions?

These conditions span the full evidence range. IBD has a high reported response rate but from weak study designs. Multiple sclerosis has clear negative Cochrane evidence. Autoimmune disease, chronic Lyme, and CIRS rest on case reports. CRPS has one supportive RCT. Lead with the study quality, not the response percentage.

Inflammatory bowel disease. Dulai and colleagues’ 2014 systematic review of 17 studies (613 patients) reported an overall clinical response of 86 percent (85 percent for Crohn’s, 88 percent for ulcerative colitis), with minor adverse events. The critical context is that these were predominantly uncontrolled case series, so the true efficacy is unknown.

“Hyperbaric oxygen produced an overall response rate of 86% in inflammatory bowel disease, but the evidence came predominantly from uncontrolled case series rather than randomized trials.”
Dulai et al., 2014, Alimentary Pharmacology & Therapeutics

Multiple sclerosis. The Cochrane review by Bennett and Heard (2004) analyzed 9 trials of 504 participants and found no consistent evidence of benefit, concluding that routine use is not justified. Some patients report symptomatic relief, but the controlled data does not support HBOT as an MS treatment. See HBOT for multiple sclerosis.

Autoimmune disease. A 2025 review by Fang and colleagues found high reported efficacy for autoimmune conditions complicated by skin ulcers, where the vascular mechanism applies, but an older randomized trial of HBOT for rheumatoid arthritis found no worthwhile benefit. The honest position is that most autoimmune evidence is case-level. Our article on HBOT for autoimmune conditions presents it directly.

CRPS. Kiralp and colleagues (2004) randomized 71 patients and found HBOT reduced pain and edema and improved wrist range of motion versus air. It is a single trial, so the finding needs replication.

Chronic Lyme and CIRS. Post-treatment Lyme disease syndrome and chronic inflammatory response syndrome are marketed with HBOT but supported only by case reports; a 2025 case report described improvement in one CIRS patient after low-pressure HBOT. We review Lyme evidence fairly in HBOT for Lyme disease without endorsing it as proven.

COPD. COPD is a special case: it is often a relative contraindication rather than an indication, because air trapping and bullae raise the risk of pulmonary barotrauma under pressure. Read HBOT for COPD for the clinical considerations before assuming it helps.

How Much Does HBOT Cost for Chronic Conditions?

For non-approved chronic indications, HBOT typically costs $150 to $300 per session, so a 40-session course runs $6,000 to $12,000 out of pocket. Insurance covers HBOT only for approved indications such as diabetic foot ulcers and radiation injury, not for off-label conditions like fibromyalgia or long COVID.

Most chronic-condition applications are off-label, which means out-of-pocket costs apply and the financial commitment is significant. Our cost guide provides a realistic framework, and the insurance coverage guide explains what is and is not covered and how to navigate prior authorization for approved indications. A standard course involves 30 to 40 sessions, five days per week, each lasting 90 minutes, so the time commitment is as real as the cost.

How Should You Decide Whether to Try HBOT?

Match the decision to the evidence. For an FDA-cleared indication, HBOT is a mainstream option worth pursuing. For an off-label chronic condition, a disciplined time-limited trial with predefined outcomes is more responsible than open-ended treatment. Optimize your primary care first, because HBOT rarely compensates for an untreated underlying condition.

Ask whether your core management plan is already optimized. If diabetes is poorly controlled, autoimmune disease is untreated, or COPD medications are not dialed in, HBOT is unlikely to make up the difference. For conditions where evidence is preliminary, structure a trial: define specific measurable outcomes, set an initial course of 20 to 30 sessions, assess formally at completion, and pre-commit to stopping if the outcomes are not met.

Testimonials deserve context. Online success stories are often genuine but subject to selection bias, since people who did not benefit rarely post. When testimonials align with positive controlled trials, as with long COVID brain fog, they carry more weight; when they describe dramatic recovery in conditions where trials show no benefit over sham, the gap should inform your decision. The placebo response in chronic conditions is real and has measurable biological correlates, which is exactly why blinded trials matter. Before starting, review the alternatives to HBOT and the relevant condition pages, including mental health, migraines, and heart health, where the evidence is thin.

Chronic conditions frequently involve neurological components. Our overview of HBOT for brain and neurological conditions covers conditions like MS and cognitive decline that intersect with systemic disease, our guide to HBOT for wound healing covers the strongest chronic indication in depth, and for how the therapy works at the level of pressure and physiology, see the complete hyperbaric chamber guide.

Seph Fontane Pennock

Author

Seph Fontane Pennock is the founder of BaricBoost.com and Regenerated.com, a clinic directory for regenerative medicine serving 10,000+ providers across the United States. He previously built and sold PositivePsychology.com, which grew to 19 million users and became the largest evidence-based positive psychology resource on the web. Seph brings direct experience as an HBOT patient, having completed protocols at clinics across three continents while navigating mold illness, systemic inflammation, and autoimmune conditions. His treatment journey includes hyperbaric oxygen therapy, peptide protocols, NAD+ therapy, and consultations with specialists from Dubai to Cape Town to Mexico. This combination of entrepreneurial track record and lived patient experience shapes everything published on BaricBoost.com. Every article is grounded in peer-reviewed research, informed by real clinical encounters, and written for patients making high-stakes treatment decisions. Seph's focus is on bringing transparency, scientific rigor, and practical guidance to the hyperbaric oxygen therapy space.

Website